These data are from a prespecified interim analysis of a prospective observational cohort study of 368 patients and may not reflect results from the final dataset.
Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. These limitations are important when interpreting results: lack of comparator arm, differences in patient populations and data collection vs randomized controlled trials.
- *OCS dose assessment was based upon data captured from medical records or patient recall, without documentation of asthma control.
- † Baseline maintenance OCS dose at initiation and/or within prior 6 months.
Unlike REALITI-A, the primary endpoint was percent reduction in daily OCS dose while maintaining asthma control. NUCALA reduced daily OCS while maintaining asthma control vs placebo (P=0.008).
Following the optimization phase, 14% of patients treated with NUCALA vs 8% treated with placebo eliminated daily OCS use while maintaining asthma control.